CVAC
CureVac N.V.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o
Market Cap: 734 Million
Primary Exchange: NASDAQ
Shares Outstanding: 224 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6866967054722495
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1070 trading days
From: 2020-12-09 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|